captopril has been researched along with scopolamine hydrobromide in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Costall, B; Coughlan, J; Horovitz, ZP; Kelly, ME; Naylor, RJ; Tomkins, DM | 1 |
| Harder, JA; Kelly, ME | 1 |
| Chopra, K; Kulkarni, SK; Raghavendra, V | 1 |
| Hagiwara, Y; Kubo, T | 1 |
| Ababei, DC; Bild, V; Bild, W; Ciobică, A; Lefter, RM; Rusu, RN | 1 |
1 review(s) available for captopril and scopolamine hydrobromide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for captopril and scopolamine hydrobromide
| Article | Year |
|---|---|
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
The effects of ACE inhibitors captopril and SQ29,852 in rodent tests of cognition.
Topics: Age Factors; Angiotensin-Converting Enzyme Inhibitors; Animals; Behavior, Animal; Captopril; Cognition; Drug Interactions; Habituation, Psychophysiologic; Male; Mice; Organophosphorus Compounds; Proline; Rats; Scopolamine; Time Factors | 1989 |
The effect of several putative cognition enhancers on a water maze acquisition deficit produced by pCPA + scopolamine combination treatment.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cholinesterase Inhibitors; Cognition; Drug Interactions; Fenclonine; Male; Maze Learning; Muscarinic Agonists; Muscarinic Antagonists; Ondansetron; Oxotremorine; Rats; Scopolamine; Serotonin Agents; Serotonin Antagonists; Tacrine | 1997 |
Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Avoidance Learning; Captopril; Dizocilpine Maleate; Electroshock; Enzyme Inhibitors; Losartan; Male; Memory; Mice; Mice, Inbred Strains; Muscarinic Antagonists; Neuroprotective Agents; NG-Nitroarginine Methyl Ester; Reaction Time; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Scopolamine | 2001 |
Tonic angiotensinergic inputs to neurons in the anterior hypothalamic area of rats.
Topics: Acetylcholine; Action Potentials; Adrenergic alpha-Agonists; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Angiotensins; Animals; Anterior Hypothalamic Nucleus; Anti-Arrhythmia Agents; Captopril; Dose-Response Relationship, Drug; Drug Interactions; Glutamic Acid; Imidazoles; Losartan; Male; Muscarinic Antagonists; Neurons; Phenylephrine; Pyridines; Rats; Rats, Wistar; Scopolamine | 2004 |
A Comparative Study on the Memory-Enhancing Actions of Oral Renin-Angiotensin System Altering Drugs in Scopolamine-Treated Mice.
Topics: Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Humans; Losartan; Male; Maze Learning; Memory Disorders; Memory, Long-Term; Memory, Short-Term; Mice; Muscarinic Antagonists; Ramipril; Renin-Angiotensin System; Scopolamine; Spatial Memory | 2019 |